LILY Loading...

From GEHC earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:30
Apr 29 ◎
Peter Arduini GEHC Q1 FY26 call
GEHC sees accelerating demand for amyloid beta imaging (Visumel) due to expanding use of disease-modifying Alzheimer's therapies, a leading indicator for the Alzheimer's diagnostics market. — Increased utilization of Alzheimer's drugs like Leqembi (Eisai/Biogen) and Kisunla (Eli Lilly) is directly driving demand for GEHC's amyloid imaging agents.
LILY
MED

About LILY Analyst Coverage

Buzzberg tracks LILY across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Peter Arduini.